Beta-hCG, Quantitative (Tumor Marker), CSF
0020730
Ordering Recommendation
 
Mnemonic
BHCG CSF
Methodology
Quantitative Electrochemiluminescent Immunoassay
Performed
Sun-Sat
Reported
Within 24 hours  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
CSF. Also acceptable: CSF collected in plain red or green (sodium or lithium heparin).  
Specimen Preparation
Transfer 0.5 mL CSF to an ARUP Standard Transport Tube. (Min: 0.3 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Any other body fluids.  
Remarks
  
Stability
Ambient: 8 hours; Refrigerated: 1 week; Frozen: 1 year  
Reference Interval
18 years and older: 0-3 IU/L  
Interpretive Data
Human chorionic gonadotropin (hCG) is a valuable aid in the management of patients with trophoblastic tumors, nonseminomatous testicular tumors, and seminomas when used in conjunction with information available from the clinical evaluation and other diagnostic procedures. Increased hCG concentrations have also been observed in melanoma, carcinomas of the breast, gastrointestinal tract, lung, and ovaries, and in benign conditions including cirrhosis, duodenal ulcer, and inflammatory bowel disease. The result cannot be interpreted as absolute evidence of the presence or absence of malignant disease. The result is not interpretable as a tumor marker in pregnant females.

The combination of the specific monoclonal antibodies used in the Roche Beta HCG electrochemiluminescent immunoassay recognize the holo-hormone, "nicked" forms of hCG, the beta-core fragment, and the free beta-subunit. Although this assay is FDA cleared for use in the detection of pregnancy, it is not labeled for use as a tumor marker or with CSF specimens. The performance characteristics of this assay were determined by ARUP.

See Compliance Statement B: www.aruplab.com/CS
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
 
CPT Code(s)
84702
Components
Component Test Code*Component Chart Name
0020730Beta-hCG, CSF Quant (Tumor Marker)
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Beta-HCG CSF concentration
  • Beta-HCG CSF levels
  • Beta-HCG, CSF
  • human chorioinic gonadotropin, CSF